By Rob Curran Terns Pharmaceuticals named former Cleave Pharmaceuticals leader Amy Burroughs to its vacant chief executive role. Ms Burroughs, who previously.
/PRNewswire/ Sciwind Biosciences, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic.
Under the deal, both entities will focus on discovering and developing new therapeutics based on small interfering RNA (siRNA) technology. The partnership will identify new therapeutic targets, which are
Share this article
Share this article HANGZHOU, China and SAN FRANCISCO, July 11, 2021 /PRNewswire/ Hangzhou Sciwind Biosciences Co., Ltd., a clinical-stage, fast-growing biopharmaceutical company focusing on discovering and developing innovative therapies to treat chronic, metabolic and immunological diseases, announced today the appointment of Dr. Weidong Zhong, former co-founder and executive of Terns Pharmaceuticals, as Chief Strategy Officer and President of its US subsidiary, Sciwind Biosciences USA. Dr. Zhong is a highly accomplished industry leader with an extensive track record in discovering and developing innovative therapies to treat infectious and metabolic diseases, said Hai Pan, Ph.D., founder and CEO of Sciwind. His knowledge and expertise will be very valuable to Sciwind as we advance our differentiated product pipeline through development in China as well as in other global markets. We are thrilled to have Dr. Zhong join us at this critical time in our comp